Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Allist Pharmaceuticals, Inc. clinical trials
The registry lists 25 studies whose lead sponsor is Allist Pharmaceuticals, Inc.. 9 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 14, 2026.
Keep track of what changes. Save the Allist Pharmaceuticals, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Allist Pharmaceuticals, Inc..
- Allist Pharmaceuticals, Inc.25 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 25 of 25.
- A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1RecruitingNCT05276726Phase 1/2
- JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C MutationRecruitingNCT06416410Phase 3
- To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant ChemotherapyRecruitingNCT04853342Phase 3
- Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C MutationRecruitingNCT05288205Phase 1/2
- Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q MutationRecruitingNCT06956001Phase 3
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung CancerRecruitingNCT06955988Phase 1
- A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy(FIRMOST)RecruitingNCT07010419Phase 3
- A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain MetastasesRecruitingNCT06970639Phase 3
- A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.RecruitingNCT06008288Phase 2
- Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion MutationCompletedNCT04858958Phase 1
- Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 InsertionActive, not recruitingNCT05466149Phase 2
- A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in ChinaActive, not recruitingNCT05009329Phase 1/2
- JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C MutationActive, not recruitingNCT05194995Phase 1/2
- A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in ChinaCompletedNCT04121286Phase 1
- JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid TumorsCompletedNCT04720976Phase 1/2
- Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAG)Active, not recruitingNCT03787992Phase 3
- A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy SubjectsCompletedNCT06162169Phase 1
- Mass Balance Study of [14C]JAB-21822CompletedNCT05920941Phase 1
- A Food Effect Study of JAB-21822 in Healthy SubjectsCompletedNCT05875493Phase 1
- Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790MTerminatedNCT03452592Phase 2
- Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung CancerTerminatedNCT02973763Phase 1
- AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR MutationsTerminatedNCT03127449Not applicable
- Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion MutationWithdrawnNCT04958967Phase 1
- Study to Determine the Effect of Food on the Blood Levels of AST2818 Following Single Oral Doses in Healthy Male VolunteersCompletedNCT03926182Phase 1
- Study Evaluating the Mass Balance And Biotransformation of Single Dose[14C] AST2818 in Chinese Healthy Male VolunteersCompletedNCT03941340Phase 1